Entacapone Articles
Endo fails in FDA law suit to stop generic Opana ER in USA; Mylan settles with Orion
21 December 2012
Orion withdraws MAA for expanded Stalevo label
16 March 2009
Orion files suit blocking Wockhardt's generic Stalevo
26 January 2009
Wockhardt seeks to make generic of Orion's Stalevo in USA
15 December 2008
FDA clears two new strengths of Novartis' Stalevo
3 November 2008
Orion seek broader indication for Stalevo
21 April 2008
Orion/Novartis' Stalevo fares well in Ph III trial
4 February 2008
Higher dose of Novartis' Stalveo cleared in USA
13 August 2007
13 new drugs added to Japan's NHI list
19 March 2007
Orion Pharma sees 37% hike in 2005 profits
20 February 2006
Australian PBS new Rx listings aimed at seniors
11 April 2005
Italy OKs 79 new drugs, plans R&D promotion
7 March 2005
Orion sees sales fall for first nine months
15 November 2004
Trial to assess Stalevo in delaying dyskinesia
13 September 2004
Orion's Stalevo available in the UK
22 December 2003
EU clears Orion/Novartis' Stalevo
3 November 2003
Orion and Novartis' Stalevo shows benefits in Parkinson's disease
8 September 2003
Orion's PD therapy is approved by FDA
30 June 2003
Further news on Orion's restructuring strategy
16 June 2003
Orion posts modest sales growth
25 February 2002
Orion benefits from Pharmacia payment
7 November 2001
Orion Pharma 2nd-qtr net sales up 8.1%
13 August 2001
COMT inhibitor make levodopa delivery smoother
31 July 2001
Pharma profits well down at Orion
9 May 2001
Overseas sales boost Orion Pharma
10 November 2000
Novartis/Orion seek entacapone use in early Parkinson's disease
18 October 2000
Orion to develop combo Parkinson's drug
7 September 2000
Novartis puts in solid 1st-half performance
21 August 2000
CPMP recommends extending Tasmar ban
4 November 1999
Novartis gains FDA backing for Comtan
21 October 1999
Entacapone "approvable" in USA
21 January 1999
Orion/Novartis' Entacaptone Warning
3 December 1998
Orion's Zotepine, Comtess In UK
26 November 1998
Pharma Sales Give Novartis Boost
22 October 1998
Stock Commentary Europe
30 September 1998
Novartis' Comtan Gets European Union Approval
23 September 1998
Massive Growth For Parkinson's Market
8 December 1997
First COMT Inhibitor For Parkinson's Reaches Market
1 October 1997
UK Industry Code Of Practice Report
1 September 1997
Novartis Unveils Strong Product Pipeline
1 July 1997
Roche's Tasmar Approvable In USA
19 June 1997
Entacapone And Tolcapone Near Market Introduction
26 March 1997
Roche Enters New Product Phase With Bright Prospects
17 February 1997
....Nutrition Downturn And Currency Holds Sandoz Back
29 April 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Sandoz To License Orion Parkinson's Drug
4 March 1996
Showing 1-55 of 55 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
